I just want to note without relitigating all the data, that we don't have good data either that riluzole slows progression by 10%, nor that edaravone does so by 25%. Neither works equally well for all, starting early seems necessary for max benefit, and the "10% off what number" is a moving target, since quality of care aside from any drugs matters more than the drugs from what we are sure of as yet.
So anyone not taking the former or not considering the latter (esp. given the expense/logistics of an infused drug only approved in Japan), don't feel like you're not doing enough. There's plenty left to do, and you're probably doing it.
Best,
Laurie